Page last updated: 2024-12-11
anibamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
anibamine: a pyridine quaternary alkaloid from Aniba sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Aniba | genus | [no description available] | Lauraceae | A family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6479877 |
| CHEMBL ID | 469649 |
| CHEMBL ID | 1186558 |
| MeSH ID | M0470207 |
Synonyms (7)
| Synonym |
|---|
| anibamine |
| 1h-indolizinium, 6,8-di-(1z)-1-decenyl-2,3-dihydro-5,7-dimethyl- |
| 6,8-bis[(z)-dec-1-enyl]-5,7-dimethyl-2,3-dihydro-1h-indolizin-4-ium |
| bdbm50242053 |
| 6,8-didec-(1z)-enyl-5,7-dimethyl-2,3-dihydro-1h-indolizinium trifluoroacetic acid salt |
| CHEMBL469649 , |
| CHEMBL1186558 |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.91
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.91) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||